Philips wins court battle against shareholders over recall

by@Reuters

Summary

Philips has secured a legal victory in a Dutch court, with the court dismissing shareholder demands for an inquiry into alleged misleading disclosures and management failures linked to the company’s 2021 recall of sleep apnea devices. Shareholders claimed that Philips executives responded too slowly to the issues that led to the recall, which involved around 15 million devices that could release harmful substances. However, the Enterprise Chamber of the Amsterdam Court of Appeal found no evidence that Philips was aware of these issues before issuing warnings, reinforcing the company's position against the accusations. The recall has prompted ongoing investigations in multiple countries, including France, where authorities are looking into allegations of aggravated fraud and failure to report safety risks.

Tokens

$PHG

Analysis

Philips: Koninklijke Philips N.V. is a Dutch multinational health technology company focused on medical devices, diagnostics, and healthcare solutions. In this case, it successfully defended against shareholder demands for a formal inquiry into its management of the 2021 sleep apnea device recall and related disclosures. Bart Meijer: Bart Meijer is a Reuters journalist based in Europe who covers business, legal, and corporate developments. He reported on the Amsterdam court ruling dismissing the shareholder inquiry into Philips. Amsterdam Court of Appeal: The Enterprise Chamber of the Amsterdam Court of Appeal is a specialized Dutch court that adjudicates corporate law matters, including shareholder disputes and requests for investigations into company management. It ruled in favor of Philips, finding no indication of prior knowledge or delayed intervention by executives regarding the recalled devices. Ongoing Probes: The recall continues to face scrutiny through investigations in multiple countries, including France. Litigation Outcome: The court determined there was no evidence Philips knew about the foam issues in the sleep apnea devices long before issuing warnings.

Categories

macropolitics
View Original Tweet